NASDAQ$LFST

LifeStance Health Group Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

LifeStance reported strong performance with significant revenue growth and strategic expansions.

LifeStance Health Group, Inc. reported a strong second quarter with a 91% increase in revenue compared to the previous year. The company successfully completed its IPO and is focused on expanding access to mental health care services, adding clinicians, and opening new centers.

  • Revenue increased by 91% year over year, reaching $160.5 million.
  • Total clinicians increased by 94% year over year, with 674 net clinician adds in the second quarter.
  • Net loss was $70.0 million.
  • Adjusted EBITDA increased by 39% year over year, reaching $14.5 million.

Headline financials

Total Revenue

$161M

Previous: $45.5M+253.2%
EPS (adj)

-$0.22

Previous: -$0.01-1793.3%
Clinicians

4.0K

Previous: 2.0K+94.1%
Capital Expenditures

-$31.8M

No prior period
Free Cash Flow

-$102M

No prior period
Net Income

-$70M

Previous: -$4.34M-1512.9%
Operating Income

-$47M

Previous: $104K-45335.6%
Gross Profit

$161M

Previous: $14.2M+1032.4%
Cash & Equivalents

$276M

No prior period
Total Assets

$1.91B

No prior period

Revenue & EPS history

LifeStance · Revenue · Quarterly

$161M

Q2 2021+253.2%vs Q2 2020
Beat estimate in 7 of 11 quarters(64%)
ActualEstimate

Forward guidance

LifeStance Health initiated its financial guidance for 2021, expecting revenue between $668 million and $678 million, center margin between $198 million and $208 million, and adjusted EBITDA between $47 million and $53 million.

Tailwinds

  • Revenue growth driven by new clinician hiring and center additions.
  • Strong performance in the inaugural quarter as a public company.
  • Focus on expanding access to mental health care services.
  • Continued growth in revenue and clinician base.
  • Investments in infrastructure and operations to support long-term growth opportunities.

Headwinds

  • Change in clinician retention levels consistent with the broader healthcare industry.
  • Full-year guidance does not assume material changes in the COVID-19 pandemic.
  • Full-year guidance does not assume material changes in the current labor market conditions.
  • Loss from operations was $47.0 million, driven by stock and unit-based compensation and IPO-related expenses.
  • Net loss was $70.0 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-4.5%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+1.2%

Avg return

30 days after

42%

8 / 19 earnings

Positive

+24.6%

Q4 2023

Best reaction

-49.7%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+19.8%+7.7%+0.5%
Q4 2025+4.3%+0.0%-11.5%
Q3 2025-3.6%+29.1%+30.1%
Q1 2025-16.0%-10.7%-10.8%
Q4 2024+3.1%+6.8%-10.8%
Q3 2024+3.2%+3.8%+2.9%
Q2 2024+1.6%+6.0%+26.1%
Q1 2024-1.7%+5.9%-19.1%
Q4 2023+24.6%+21.8%-3.4%
Q3 2023-9.4%-8.9%+7.9%
Q2 2023-5.0%-7.4%-17.1%
Q1 2023-1.4%+1.1%+1.7%
Q4 2022+22.2%+23.8%+65.6%
Q3 2022-30.4%-15.9%-23.0%
Q2 2022+6.2%+10.8%+29.3%
Q1 2022-13.9%+0.4%+10.1%
Q4 2021-12.7%-5.9%+4.2%
Q3 2021-27.3%-22.8%-29.1%
Q2 2021-49.7%-40.6%-30.2%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro